ICYMI: Liveyon Pure-Cast Answers The Most Popular Questions About Stem Cells

Created to spotlight the developing stem cell industry with an in-depth look at common misconceptions, scientific breakthroughs and advancements, and popular issues and concerns, the Liveyon Pure-Cast video podcast recently answered the most popular questions popping up around the stem cell industry.

Liveyon Founder and CEO John Kosolcharoen and Director of Education Dr. Alan Gaveck provide answers to basic questions about stem cells in an attempt to shed light on the regenerative industry.

Here are some of the questions answered:

1.Will I have an inflammatory response?

Dr. Alan Gaveck

Dr. Gavick: “While it’s not uncommon to have an inflammatory response, you don’t necessarily have to have it. And the reason for the inflammatory response, is people need to remember these cells are a heterogeneous mix of cells, and part of those are polymorphonuclear sites, and a component of a polymorphonuclear site is a neutrophil, and a neutrophil can stimulate prostaglandins.”

2.I’m in a lot of pain and I want to get a stem cell treatment— Does it hurt?

Dr. Gavick: “The shot doesn’t hurt any more than anything else.”

John Kosolcharoen

 John Kosolcharoen: “Right, people go and get steroid injections and the only difference between a steroid injection and a stem cell injection is they’re stem cells instead of steroids.”

3. How many treatments do I need and when will I start feeling it?

Dr. Gavick: “We know statistically, approximately 86 percent of the patients who have joint injection only need one. However, if you’re in the other 14%, you’re still 100%. You’ve still got to have another one. And how long does it take? It can take a while. I usually tell doctors if they talk to their patients in the terms of weeks and months to look for healing and improvement, they’re going to have happy patients. If you talk in the terms of hours and days, no, they’re not going to be happy.”

Dr. Gavick and Kosolcharoen’s discussion ranged a full slate of topics covering frequently asked question in the stem cell industry. You can view the entre discussion here.

‘Liveyon launched ‘Liveyon Pure Cast,’ to bring to light the truth about this emerging field and connecting doctors, researchers, patients, and the general public directly with well-respected industry leaders. The podcast provides a complimentary resource for clients of the company’s new product line.

The exclusive video series streams live every Monday, Wednesday and Friday morning and features John Kosolcharoen, founder and chief executive officer of Liveyon and Dr. Alan Gaveck, director of education, Liveyon. Dr. Gaveck brings 13 years of experience in both clinical and surgical medical treatments and the two hosts’ intellectual chemistry enhances the show’s format, as they tackle groundbreaking topics and introduce experts in the field of regenerative medicine, including leading researchers and physicians.

Founded in 2016, Liveyon is pushing the boundaries of regenerative medicine with its innovative take on product research and development, manufacturing and distribution, and commitment to safety and transparency. Liveyon and Liveyon Labs Inc. are committed to achieving unparalleled stem cell potency through high live nucleated cell counts, while following validation protocols that produce an extremely consistent product for the most efficacious outcomes. The company’s dynamic ability to adapt to changing market trends and execute on opportunities has fortified its exponential growth and the company is poised to continue making a huge impact in the industry 2019.

To stay up-to-date on the regenerative medicine industry and receive notices of free upcoming live streaming video events, please subscribe to ‘Liveyon Pure-Cast.’

For more Liveyon Pure Cast Podcast videos subscribe to our YouTube channel at:

Want to learn more about Liveyon Stem Cells? Contact us for more information.

Translate »


Medical Professional Viewing Only (Disclaimer)

This site was intended for education purposes only and strictly for use by medical professionals. The FDA recently re-confirmed, there is only one registered stem cell product, and while there is enormous promise in stem cell therapies, and thousands of ongoing experimental applications trying to establish efficacy, these are not at the point where they would meet the scientific standard.
The FDA has stated:
Stem cells, like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood forming stem cells) for certain indications.
This site is not intended for consumers.
If you are considering stem cell treatment in the U.S., ask your physician if the necessary FDA approval has been obtained or if you will be part of an FDA-regulated clinical study. This also applies if the stem cells are your own. Even if the cells are yours, there are safety risks, including risks introduced when the cells are manipulated after removal.
“There is a potential safety risk when you put cells in an area where they are not performing the same biological function as they were when in their original location in the body.” Cells in a different environment may multiply, form tumors, or may leave the site you put them in and migrate somewhere else.
If you are considering having stem cell treatment in another country, learn all you can about regulations covering the products in that country. Exercise caution before undergoing treatment with a stem cell-based product in a country that—unlike the U.S.—may not require clinical studies designed to demonstrate that the product is safe and effective. FDA does not regulate stem cell treatments used solely in countries other than the United States and typically has little information about foreign establishments or their stem cell products.
Stem cell therapies have enormous promise, but the science in each use is still in the developmental stage. Professional judgment and expertise is needed in using stem cells for any therapeutic use, and we urge anyone embarking on the use of stem cell therapies to consult the national health data bases to evaluate current information from clinical trials and the FDA websites on human tissue should also be consulted to get its current evaluation of any therapy.